Marc Siegel, Founder and President

Mr. Marc D. Siegel has over thirty years of experience in the healthcare industry. In 1990, he co-founded and served as President of BIS Laboratories, a biotechnology company which provided novel cancer diagnostic services based upon the detection and characterization of circulating tumor cells. In 1998, BIS was acquired by IMPATH, a national reference laboratory, where he oversaw its successful integration with the larger entity. As a senior member of IMPATH’s management team, he directed the development of IMPATH’s Predictive Oncology unit, expanded its CLIA laboratory testing offering, oversaw the development of disease-specific diagnostic products, and spearheaded the company’s evaluation and acquisition of novel diagnostic technology platforms/companies. Together, his efforts drove a rapid increase of IMPATH’s revenues from $37 million to $200 million.

Mr. Siegel also served as the President of DomaniCell, a stem cell collection and storage company and Vice-President of Business Development for CymogenDx, a novel molecular probe manufacturing company. He currently advises many healthcare companies including those working in nanotechnology, molecular and cellular assays, stem cell and cord blood collection, anti-cancer compounds and vaccines, and technology licensing. He has served on the advisory board of therapeutic and diagnostic development companies as well as advised venture capitalists on mergers and acquisitions.

Mr. Siegel received his MBA from the Anderson School of Business at UCLA.